Most Common Mood Stabilizer in Children and Adolescents
In community practice settings, anticonvulsants (particularly valproate) and atypical antipsychotics are the most commonly used mood stabilizers in children and adolescents, despite lithium being the only FDA-approved mood stabilizer for youth aged 12 and older. 1
FDA Approval vs. Real-World Practice
There is a significant disconnect between regulatory approval and actual clinical practice:
- Lithium is the only mood stabilizer with FDA approval for bipolar disorder in youth (age 12+) for both acute mania and maintenance therapy 1
- However, in community settings, anticonvulsants and atypical antipsychotics are the agents used most often 1
Specific Usage Patterns from Research Data
A community-based study of 111 children and adolescents with bipolar disorder revealed the following medication trial frequencies 2:
- Valproate: 79% (most common)
- Lithium: 51%
- Gabapentin: 29%
- 98% had tried a mood stabilizer or anticonvulsant at some point
Comparative Efficacy Data
When directly compared in pediatric populations, response rates for mania and mixed episodes were 1:
- Valproate: 53%
- Lithium: 38%
- Carbamazepine: 38%
This explains why valproate has become the most commonly used mood stabilizer in clinical practice—it demonstrates superior response rates in head-to-head comparisons with lithium in youth.
Important Clinical Caveats
The Polypharmacy Reality
Children and adolescents with bipolar disorder are typically treated with multiple medications (mean 3.40 medications), having undergone an average of 6.32 psychotropic medication trials 2. This reflects the complexity of treating pediatric bipolar disorder and the frequent need for combination therapy.
Evidence Quality Limitations
Despite widespread use, none of the mood stabilizers has been well studied in juveniles 1. The evidence base consists primarily of:
- Small, positive double-blind studies for lithium with diagnostic variability
- Open-label trials and case reports for anticonvulsants
- Limited controlled data overall
Lithium's Questionable Long-Term Efficacy
One controlled discontinuation trial found high relapse rates in both lithium-continuation and placebo groups, raising questions about lithium's ongoing efficacy in adolescents 1
Current Treatment Approach
The standard approach based on AACAP guidelines recommends starting with FDA-approved agents (lithium, valproate, or atypical antipsychotics), recognizing that evidence in children and adolescents is sparse 1. The choice should be guided by efficacy data, side effect profile, and the specific clinical presentation rather than FDA approval status alone.
Given the superior response rates and widespread community use, valproate has emerged as the de facto most common mood stabilizer in pediatric practice, despite lithium's unique regulatory status.